🔎 Trials Near Me

Home › Non-Small Cell Lung Cancer › New Hampshire

Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa New Hampshire

17 pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa mga site sa New Hampshire.

Mga Lungsod sa New Hampshire

Opisyal na teksto ng pag-aaral (English)

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center /ID# 277673, Lebanon
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07155187

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT04267848

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Dartmouth-Hitchcock Medical Center, Lebanon
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06881784

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06667076

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06890598

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Lebanon
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06767514

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • Dartmouth Hitchcock Medical Center, Lebanon
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • Dartmouth Hitchcock Medical, Lebanon
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Dartmouth-Hitchcock Medical Center, Lebanon
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06119581

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04165798

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

  • Dartmouth Hitchcock Medical Center ( Site 0016), Lebanon
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04165070

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon
  • Solinsky Center for Cancer Care, Manchester
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • New Hampshire Oncology Hematology PA-Concord, Concord
  • Solinsky Center for Cancer Care, Manchester
Nagre-recruitPhase 2
18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

  • Dartmouth Hitchcock, Lebanon
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06362369

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

  • Dartmouth Hitchcock Medical Center, Lebanon
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT05948865

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.